secwatch.observer — SEC 8-K summary
======================================

Issuer:     Singular Genomics Systems, Inc. (—)
CIK:        0001850906
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059523
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Singular Genomics Q1 2024: revenue $0.4M, net loss $25.0M ($0.34/share), G4X launch planned for 2025
--------------------------------------------------------------------------------

- Revenue of $0.4M from one instrument capital purchase and consumables; negative gross margin of $0.4M.
- Net loss $25.0M ($0.34 per share) vs $23.6M ($0.33) in Q1 2023.
- Shipped six G4 systems in Q1, total commercial placements at 30; G4X spatial sequencer launch targeted for 2025.
- Operating expenses $26.4M; cash and investments $150.7M as of March 31, 2024.
- Management highlighted new G4X data at AACR and ABRF conferences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850906/000095017024059523/0000950170-24-059523-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850906/000095017024059523/omic-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059523

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer